Urology Trials

A list of our early phase urology trials which are open to recruitment at University College London Hospitals.

Additional early phase clinical trials recruiting Urology cohorts may be found in the Advanced Solid Tumour Trials Portfolio page.

DURANCE DURANCE: A phase Ib/II study to assess the safety and activity of DURvalumab (MEDI4736) in combination with S-488210/S-488211 vAccine in Non-muscle invasive bladder CancEr
IRAS Number	263559
Principal Investigator:	Prof. Mark Linch
Drug Class/ Treatment:	Durvalumab (PD-L1 Blocking IgG1 Kappa Monoclonal Antibody) + S-488210/S-488211 (Peptide Vaccine)
Patient Population:	Non-Muscle Invasive Bladder Cancer
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

ABACUS-2 ABACUS-2: Phase 2 study of neoadjuvant immune checkpoint inhibitors in urothelial cancer
IRAS Number:	1003489
Principal Investigator:	Prof. Mark Linch
Drug Class/ Treatment:	Atezolizumab (IgG1 Isotype Monoclonal Antibody against PD-L1)
Patient Population:	Patient requiring surgery with: Cohort 1: T1 high grade - T4a of the bladder with mixed (dominant) or rare histological subtype Cohort 2: Upper urinary tract (high grade or high risk)
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)